{"id":75107,"date":"2023-10-31T12:43:17","date_gmt":"2023-10-31T16:43:17","guid":{"rendered":"https:\/\/hitconsultant.net\/?p=75107"},"modified":"2023-10-31T12:43:22","modified_gmt":"2023-10-31T16:43:22","slug":"phasev-raises-15m-for-ml-driven-clinical-trial-optimization","status":"publish","type":"post","link":"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/","title":{"rendered":"PhaseV Raises $15M for ML-Driven Clinical Trial Optimization"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" width=\"1500\" height=\"521\" src=\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2786-1500x521.png\" alt=\"\" class=\"wp-image-75108\" srcset=\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2786-1500x521.png 1500w, https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2786-300x104.png 300w, https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2786-290x101.png 290w, https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2786-768x267.png 768w, https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2786-1536x533.png 1536w, https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2786.png 1898w\" sizes=\"(max-width: 1500px) 100vw, 1500px\" \/><\/figure>\n\n\n\n<p><strong>What You Should Know:<\/strong><\/p>\n\n\n\n<ul><li><a href=\"https:\/\/phasevtrials.com\/\">PhaseV<\/a>&nbsp;a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has raised $15 million in funding, led by Viola Ventures and Exor Ventures, including participation from LionBird and a group of prominent angel investors.<\/li><li>A recent Deloitte&nbsp;<a href=\"https:\/\/www2.deloitte.com\/ch\/en\/pages\/press-releases\/articles\/deloitte-pharma-study-drop-off-in-returns-on-r-and-d-investments-sharp-decline-in-peak-sales-per-asset.html\">study<\/a>&nbsp;estimates the average cost of developing a single new drug at $2.3 billion in 2022, with an average 7.1 year deployment time. Moreover, the vast majority of drug candidates do not reach the finish line, and many fail the clinical phase even though the biology works.<\/li><\/ul>\n\n\n\n<p><strong>Optimising Clinical Trial Design to Improve Overall Efficacy<\/strong><\/p>\n\n\n\n<p>PhaseV tackles this challenge by leveraging proprietary ML technology that provides clinical development teams an advanced ability to retrospectively analyze and optimally design studies, as well as adapt in real-time throughout the trial. This ML-driven adaptive process can significantly accelerate the clinical drug development process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials.<\/p>\n\n\n\n<p>&#8220;Clinical trials are the most time-consuming and costly stages of drug development, and many trials fail due to inherent uncertainties and complexities in trial design and execution,&#8221;&nbsp;<strong>said Noam Ohana, Managing Director at Exor Ventures,<\/strong>&#8220;PhaseV has demonstrated its technological prowess and commitment to reshaping the landscape of clinical trial design and analysis to ensure that promising drugs reach their full potential.&#8221;<\/p>\n\n\n\n<p>PhaseV offers two distinct service lines for AI clinical trial optimization. The first includes assessing the potential impact of adaptive trial design on the proposed study, followed by optimal design and execution. The second involves retrospective analysis that detects hidden signals in clinical trial data and evaluates endpoints and subpopulations to redefine success or failure of a trial. Leveraging a wide range of parameters, this multifaceted approach is also valuable for drug repurposing efforts. The company&#8217;s approach has proven valuable in a variety of therapeutic areas including oncology, endocrinology, autoimmune diseases, rare diseases and more.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>What You Should Know: PhaseV&nbsp;a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has raised $15 million in funding, led by Viola Ventures and Exor Ventures, including participation from LionBird and a group of prominent angel investors. A recent Deloitte&nbsp;study&nbsp;estimates the average cost of developing <a class=\"more-posts-link\" href=\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/\">&#8230; Read More<\/a><\/p>\n","protected":false},"author":94,"featured_media":75108,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"categories":[1117],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.6 (Yoast SEO v20.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>PhaseV Raises $15M for ML-Driven Clinical Trial Optimization -<\/title>\n<meta name=\"description\" content=\"PhaseV\u00a0a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that i..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PhaseV Raises $15M for ML-Driven Clinical Trial Optimization\" \/>\n<meta property=\"og:description\" content=\"PhaseV\u00a0a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that i..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-31T16:43:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-31T16:43:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2786.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1898\" \/>\n\t<meta property=\"og:image:height\" content=\"659\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Syed Hamza Sohail\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hitconsultant\" \/>\n<meta name=\"twitter:site\" content=\"@hitconsultant\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Syed Hamza Sohail\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/\"},\"author\":{\"name\":\"Syed Hamza Sohail\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/2c3b22c89b4967fe57f40b1f2fecab8f\"},\"headline\":\"PhaseV Raises $15M for ML-Driven Clinical Trial Optimization\",\"datePublished\":\"2023-10-31T16:43:17+00:00\",\"dateModified\":\"2023-10-31T16:43:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/\"},\"wordCount\":334,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/hitconsultant.net\/#organization\"},\"articleSection\":[\"Health IT\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/\",\"url\":\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/\",\"name\":\"PhaseV Raises $15M for ML-Driven Clinical Trial Optimization -\",\"isPartOf\":{\"@id\":\"https:\/\/hitconsultant.net\/#website\"},\"datePublished\":\"2023-10-31T16:43:17+00:00\",\"dateModified\":\"2023-10-31T16:43:22+00:00\",\"description\":\"PhaseV\u00a0a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that i..\",\"breadcrumb\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hitconsultant.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health IT\",\"item\":\"https:\/\/hitconsultant.net\/category\/health-it\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"PhaseV Raises $15M for ML-Driven Clinical Trial Optimization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hitconsultant.net\/#website\",\"url\":\"https:\/\/hitconsultant.net\/\",\"name\":\"\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/hitconsultant.net\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hitconsultant.net\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/hitconsultant.net\/#organization\",\"name\":\"HIT Consultant Media\",\"url\":\"https:\/\/hitconsultant.net\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png\",\"contentUrl\":\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png\",\"width\":\"1024\",\"height\":\"772\",\"caption\":\"HIT Consultant Media\"},\"image\":{\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409\",\"https:\/\/twitter.com\/hitconsultant\",\"http:\/\/www.linkedin.com\/company\/2489253\",\"https:\/\/www.pinterest.com\/hitconsultant\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/2c3b22c89b4967fe57f40b1f2fecab8f\",\"name\":\"Syed Hamza Sohail\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e3b32d24fb71fbe1a5b4e21c51b7ca22?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e3b32d24fb71fbe1a5b4e21c51b7ca22?s=96&d=mm&r=g\",\"caption\":\"Syed Hamza Sohail\"},\"url\":\"https:\/\/hitconsultant.net\/author\/ssohail\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PhaseV Raises $15M for ML-Driven Clinical Trial Optimization -","description":"PhaseV\u00a0a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that i..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/","og_locale":"en_US","og_type":"article","og_title":"PhaseV Raises $15M for ML-Driven Clinical Trial Optimization","og_description":"PhaseV\u00a0a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that i..","og_url":"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/","article_publisher":"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409","article_published_time":"2023-10-31T16:43:17+00:00","article_modified_time":"2023-10-31T16:43:22+00:00","og_image":[{"width":1898,"height":659,"url":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2786.png","type":"image\/png"}],"author":"Syed Hamza Sohail","twitter_card":"summary_large_image","twitter_creator":"@hitconsultant","twitter_site":"@hitconsultant","twitter_misc":{"Written by":"Syed Hamza Sohail","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/#article","isPartOf":{"@id":"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/"},"author":{"name":"Syed Hamza Sohail","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/2c3b22c89b4967fe57f40b1f2fecab8f"},"headline":"PhaseV Raises $15M for ML-Driven Clinical Trial Optimization","datePublished":"2023-10-31T16:43:17+00:00","dateModified":"2023-10-31T16:43:22+00:00","mainEntityOfPage":{"@id":"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/"},"wordCount":334,"commentCount":0,"publisher":{"@id":"https:\/\/hitconsultant.net\/#organization"},"articleSection":["Health IT"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/","url":"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/","name":"PhaseV Raises $15M for ML-Driven Clinical Trial Optimization -","isPartOf":{"@id":"https:\/\/hitconsultant.net\/#website"},"datePublished":"2023-10-31T16:43:17+00:00","dateModified":"2023-10-31T16:43:22+00:00","description":"PhaseV\u00a0a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that i..","breadcrumb":{"@id":"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hitconsultant.net\/2023\/10\/31\/phasev-raises-15m-for-ml-driven-clinical-trial-optimization\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hitconsultant.net\/"},{"@type":"ListItem","position":2,"name":"Health IT","item":"https:\/\/hitconsultant.net\/category\/health-it\/"},{"@type":"ListItem","position":3,"name":"PhaseV Raises $15M for ML-Driven Clinical Trial Optimization"}]},{"@type":"WebSite","@id":"https:\/\/hitconsultant.net\/#website","url":"https:\/\/hitconsultant.net\/","name":"","description":"","publisher":{"@id":"https:\/\/hitconsultant.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hitconsultant.net\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/hitconsultant.net\/#organization","name":"HIT Consultant Media","url":"https:\/\/hitconsultant.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/","url":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png","contentUrl":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png","width":"1024","height":"772","caption":"HIT Consultant Media"},"image":{"@id":"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409","https:\/\/twitter.com\/hitconsultant","http:\/\/www.linkedin.com\/company\/2489253","https:\/\/www.pinterest.com\/hitconsultant\/"]},{"@type":"Person","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/2c3b22c89b4967fe57f40b1f2fecab8f","name":"Syed Hamza Sohail","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e3b32d24fb71fbe1a5b4e21c51b7ca22?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e3b32d24fb71fbe1a5b4e21c51b7ca22?s=96&d=mm&r=g","caption":"Syed Hamza Sohail"},"url":"https:\/\/hitconsultant.net\/author\/ssohail\/"}]}},"_links":{"self":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts\/75107"}],"collection":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/users\/94"}],"replies":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/comments?post=75107"}],"version-history":[{"count":0,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts\/75107\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/media\/75108"}],"wp:attachment":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/media?parent=75107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/categories?post=75107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/tags?post=75107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}